User:Nzamel/Hymenolepis diminuta

Hymenolepis diminuta has been shown to protect patients from colitis by diminshing the host's inflammatory response. H. diminuta accomplish this by producing a high amount of regulatory IL-10 cells, B cells, and T cells. Addittionaly, H.diminuta have the capability of activating mucousal immunity. H. diminuta does not disrupt the intestinal epithelium, and these species are considered a great model for helmith therapy because they are inexspensive to maintain in a lab. Research performed on rats after infecting them with H.diminuta showed that the rats' neurological functions were protected against stress and other factors. According to recent research, these organisms can protect the immunity of their hosts (laboratory animals) without causing adverse effects.

Research also shows that the specific theraputic life cycle of Hymenolepis can be purified using Hymenolepis diminuta cysticercoids. Purificaiton is crucial to recieve approval to clinically use these organisms. Hymenolepis diminuta cysticercoids (HDCs) with varying dosages have been adminstrated in humans during different trials under the supervision of medical doctors. The researchers gradually increased the dosages of HDCs until the patients reported relief from symptoms. The frequency of the dosages was approxamitely between 3 and 6 weeks. It was found that 50 percent of patients with inflmmatory diseases benefited from HDCs treatment. Other conditions that were successfully treated were anxiety disorders and other neuropysological diseases.